GLP-1 weight loss claims on TikTok: what the science actually supports

What did @twomomsarebetterthanone_ actually say?

Honestly, not much. The transcript is just a repeated lyric-style phrase: "I took the drugs and the drugs are working, took the drugs and the drugs are working." That's it. There's no dosing information, no mechanism explained, no timeline, no baseline weight disclosed. The caption does the heavier lifting, tagging both semaglutide and tirzepatide and inviting followers to DM for "how you can get started on it right now." That's where this goes from a personal testimonial into something that raises real regulatory flags.

The creator appears to be expressing genuine gratitude for a weight-loss result. That part is relatable. Millions of people have had real, meaningful responses to GLP-1 receptor agonists. But the video's actual informational content is essentially zero, and the call to action, drop a emoji and message me for access, suggests they may be funneling followers to a prescriber or a compounding source, which is a different thing entirely from sharing a personal story.

Does the science back this up?

GLP-1 receptor agonists are among the most rigorously studied drug classes in recent obesity medicine. The evidence is strong. But "the drugs are working" is doing a lot of vague lifting here, and the science shows the picture is more complicated than a catchy refrain suggests.

Semaglutide (the active ingredient in Wegovy and Ozempic) showed a mean body weight reduction of 14.9% over 68 weeks versus 2.4% for placebo in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide, studied in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), showed up to 20.9% mean weight reduction at the highest dose. Those are real numbers. The drugs work for a significant portion of patients.

What the science also shows: roughly 10-15% of patients are low or non-responders (Rubino et al., 2022, Nature Medicine). Side effects, including nausea, vomiting, and gastroparesis, lead to discontinuation in a meaningful subset. Weight typically returns after stopping the medication, with Wilding et al. (2022, Diabetes, Obesity and Metabolism) showing most weight regained within a year of cessation. "Working" is real, but it's not universal and it's not permanent by default.

What did they get wrong (or right)?

Credit where it's due: GLP-1 medications genuinely do work for many people, and personal testimony has value. The frustration with decades of failed dieting that underlies "reclaim your life" messaging reflects a real clinical reality, that obesity has strong biological drivers that willpower alone doesn't fix. That framing is actually more accurate than the old "just eat less" advice.

But here's what's wrong, and it matters. The caption solicits followers with a call to "get started on it right now" via DM. That is not how prescription medication should be initiated. GLP-1 receptor agonists require a licensed prescriber, a medical history review, and screening for contraindications including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, per FDA labeling for both Wegovy and Zepbound. Routing people through a social media DM to access injectable prescription drugs bypasses that entirely.

The video also tags both semaglutide and tirzepatide without distinguishing them. These are different molecules with different mechanisms, dosing schedules, and side effect profiles. Treating them as interchangeable in a recruitment post is sloppy at best.

What should you actually know?

If you're considering a GLP-1 medication, the evidence supporting them is genuinely good. But "the drugs are working" for one person on TikTok tells you almost nothing about whether they'll work for you, at what dose, or for how long.

A few things worth knowing before you DM anyone. First, compounded semaglutide and tirzepatide, which flooded the market during FDA shortage periods, are not equivalent to FDA-approved brand-name drugs. The FDA has explicitly warned that compounded versions are not approved and have not been evaluated for safety or efficacy. Do not let anyone tell you otherwise. Second, these medications work best alongside behavioral support. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained results over two years, but participants received lifestyle counseling alongside the drug. Third, stopping the medication typically means weight returns. That's not a failure of willpower. It reflects the chronic nature of obesity as a disease.

The right starting point is a licensed clinician who reviews your actual medical history, not a comment section.